Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline afte...

Diabetes: Recent studies reveal that metformin may influence blood sugar management via the brain. This medication stimulates a distinct br...

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...

Eli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

Fifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes man...

The diabetes treatment landscape in India is on the brink of transformation. Innovative GLP-1 medications are set to redefine therapy stand...

Obesity, weight-loss medicines: Novo has been scrambling to keep pace in the obesity drug race it started, losing ground to rival Eli Lilly...

Lilly stock latest news: Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year gu...

Driven by the success of Wegovy and Mounjaro, numerous pharma companies are developing anti-obesity drugs, with over 170 in various stages....

Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participant...

India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenge...

Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess ...

According to research firm Pharmarack, the market has tripled in two years after witnessing a sluggish growth till 2021. Over the last five...

Novo Nordisk's weight-loss drug, Wegovy, which has so far only been available as an injection, may soon come in pill form. Clinical trials ...

Novo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in India for treatment of type 2 diabetes.

The product is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, ...